4121.TWO Rossmax International Ltd
- Market cap
- TWD 993M
- P/E
- -
- P/B
- 0.74x
- ROE
- -3.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4121.TWO undervalued?
Graham numberThe Graham number of Rossmax International Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rossmax International Ltd fundamental analysis
No fundamental analysis for Rossmax International Ltd yet.
Rossmax International Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rossmax International Ltd
Rossmax International Ltd. develops and supplies healthcare products and solutions. The company offers body fat monitors and scales that are used to measure body fat, body mass index, lean mass, muscle mass, and water ratio along with body weight; blood pressure monitors; sphygmomanometer, a device that measures blood pressure; stethoscope, an acoustic medical device for auscultation, or listening to the internal sounds of an animal or human body; pulse oximeter monitors to …
Full company profileRossmax International Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rossmax International Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 3.15B | 3.10B | 3.09B | 3.68B | 3.95B | 4.34B | 3.81B | 3.85B | 3.80B | 3.77B |
| Gross Profit | 963M | 955M | 983M | 1.23B | 1.30B | 1.51B | 1.27B | 1.33B | 1.31B | 1.28B |
| Operating Income | 15.2M | -7.59M | -1.46M | 201M | 181M | 298M | 39.1M | -76.7M | -72.4M | -96.5M |
| EBITDA | 119M | 100M | 277M | 430M | 426M | 582M | 345M | 308M | 308M | 299M |
| Net Income | 27.7M | 16.6M | 25.7M | 135M | 111M | 170M | -6.67M | -29.3M | -29.9M | -51.4M |
| EPS | 0.37 | 0.22 | 0.35 | 1.83 | 1.31 | 2.00 | -0.08 | -0.34 | -0.36 | -0.62 |
| Balance Sheet | ||||||||||
| Total Assets | 2.41B | 2.30B | 3.06B | 3.36B | 3.76B | 3.99B | 4.09B | 4.23B | 4.21B | 4.00B |
| Total Liabilities | 1.06B | 958M | 1.73B | 1.70B | 1.98B | 2.05B | 2.24B | 2.14B | 2.22B | 2.09B |
| Shareholders' Equity | 1.14B | 1.12B | 1.12B | 1.34B | 1.45B | 1.55B | 1.44B | 1.48B | 1.41B | 1.38B |
| Cash & Short-term Investments | 539M | 409M | 28.5M | 1.06B | 917M | 816M | 691M | 594M | 614M | 522M |
| Total Debt | - | - | - | 937M | 1.08B | 1.12B | 1.39B | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -97.6M | 23.6M | 81.9M | 459M | 575M | 434M | 302M | 314M | 284M | 285M |
| Capital Expenditure | 38.6M | 46.5M | 41.5M | 81.6M | 350M | 135M | 107M | 75.6M | 47.5M | 43.0M |
| Free Cash Flow | -138M | -32.1M | 39.7M | 378M | 226M | 300M | 195M | 239M | 237M | 242M |
| Ratios | ||||||||||
| ROE | 2.4% | 1.5% | 2.3% | 10.1% | 7.7% | 11.0% | -0.5% | -2.0% | -2.1% | -3.7% |
| ROA | 1.1% | 0.7% | 0.8% | 4.0% | 3.0% | 4.3% | -0.2% | -0.7% | -0.7% | -1.3% |
| Net Profit Margin | 0.9% | 0.5% | 0.8% | 3.7% | 2.8% | 3.9% | -0.2% | -0.8% | -0.8% | -1.4% |
| Debt to Equity | - | - | - | 0.70x | 0.75x | 0.72x | 0.96x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Rossmax International Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 12, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | TWD 48.8M | 0.57 | - |
| 2023 | TWD 102M | 1.20 | - |
| 2022 | TWD 92.8M | 1.09 | 54.5% |
| 2021 | TWD 95.2M | 1.12 | 85.5% |
| 2020 | TWD 14.7M | 0.20 | 10.8% |
| 2019 | TWD 7.33M | 0.10 | 28.5% |
| 2018 | TWD 21.9M | 0.30 | 131.8% |
| 2017 | TWD 21.9M | 0.30 | 79.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.04:1 on Aug 10, 2011.
Who owns Rossmax International Ltd
- Insiders 41.81%
- Institutions 0.00%
- Public & others 58.19%
- Shares outstanding 83.1M
- Free float 52.5M
Rossmax International Ltd company profile
- Company name
- Rossmax International Ltd
- Ticker
- 4121.TWO
- ISIN
- TW0004121009
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- No. 189, Kang Chien Road, Taipei, Taiwan, 114
- Phone
- 886 2 2659 7888
- Website
- rossmax.com
About Rossmax International Ltd
Rossmax International Ltd. develops and supplies healthcare products and solutions. The company offers body fat monitors and scales that are used to measure body fat, body mass index, lean mass, muscle mass, and water ratio along with body weight; blood pressure monitors; sphygmomanometer, a device that measures blood pressure; stethoscope, an acoustic medical device for auscultation, or listening to the internal sounds of an animal or human body; pulse oximeter monitors to measure the amount of oxygen carried in the body; non-contact telephoto thermometers used to measure human body temperature; and blood glucose monitoring system, a medical device for determining the approximate concentration of glucose in the blood. It also provides nebulizer, a drug delivery device used to administer medication in the form of a mist; suction unit, a machine used to remove mucus and other bodily fluids; aero spacer, a device used to increase the ease of administering aerosolized medication; peak flow meter, a device used to monitor a person's ability to breathe out air; heating pads used for therapy; and anti-decubitus mattresses, as well as provides breast pumps. In addition, the company operates Rossmax healthstyle app, which allows customers to monitor blood pressure, blood glucose, SpO2, weight, and temperature through a single app. It provides healthcare products in the fields of cardiovascular, diabetes, respiratory, fever, and wound healing diseases, as well as thermometers, scales, and nebulizers fo. The company also exports its products. It operates in Taiwan, America, Europe, East Asia, South Asia, India, Middle East, Africa, and internationally. Rossmax International Ltd. was founded in 1988 and is based in Taipei, Taiwan.
Rossmax International Ltd management
9- Mr. Chih-Ping LiuChairman of the Board & GM
- Ms. Cherry ChangDeputy GM of Finance Dept., & Corporate Governance Supervisor
- Mr. Gary HungR&D Associate Manager
- Ms. Yolanda LinProduct and Quality Department Associate Manager
- Mr. Chuan ying WangR&D Associate Manager
- C. D. LeeSales Manager
- Mr. Kuan Yu ChuVice President and Associate Manager
- Mr. Adeb TsaoVP & Associate Manager
- Mr. Bill WangSpecial Assistant